Expert: CSL to closely watch Grifols-Talecris deal

06/8/2010 | Business Spectator (Australia)

CSL's Brian McNamee is expected to closely watch the move by Spanish firm Grifols to acquire Talecris and its possible effect on his company, Stephen Bartholomeusz writes in this Business Spectator commentary. The finalization of the acquisition could mean that the intravenous immunoglobulin market would be dominated by three key players with almost similar market shares, namely Baxter, CSL and Grifols, Bartholomeusz writes.

View Full Article in:

Business Spectator (Australia)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
San Jose, CA
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA